Best Biotech Stocks To Watch Today – April 21st

AbbVie, Danaher, Thermo Fisher Scientific, Vertex Pharmaceuticals, and Dogwood Therapeutics are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that leverage biotechnology to develop medical therapies, diagnostics, and other healthcare or agricultural products. These stocks are often characterized by high volatility due to the risks associated with research and development, regulatory approvals, and competitive market dynamics, yet they offer potential for significant returns if breakthroughs occur. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded down $2.61 during trading hours on Monday, reaching $170.38. The stock had a trading volume of 1,988,237 shares, compared to its average volume of 5,989,680. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The firm’s 50 day moving average is $198.47 and its 200-day moving average is $187.71. The stock has a market capitalization of $301.40 billion, a price-to-earnings ratio of 70.99, a P/E/G ratio of 1.62 and a beta of 0.55. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR stock traded down $4.82 during trading on Monday, hitting $182.01. 1,491,987 shares of the company’s stock were exchanged, compared to its average volume of 3,322,356. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher has a 52-week low of $171.00 and a 52-week high of $281.70. The business has a 50-day moving average price of $201.99 and a two-hundred day moving average price of $226.60. The stock has a market capitalization of $130.08 billion, a price-to-earnings ratio of 34.47, a PEG ratio of 2.66 and a beta of 0.86.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded down $10.16 during mid-day trading on Monday, hitting $417.34. 587,368 shares of the stock were exchanged, compared to its average volume of 1,710,658. Thermo Fisher Scientific has a 12-month low of $409.85 and a 12-month high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $157.54 billion, a price-to-earnings ratio of 25.25, a P/E/G ratio of 2.99 and a beta of 0.86. The stock’s fifty day simple moving average is $497.67 and its two-hundred day simple moving average is $532.62.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

NASDAQ VRTX traded down $6.62 on Monday, reaching $482.48. The stock had a trading volume of 261,584 shares, compared to its average volume of 1,326,155. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock has a market cap of $123.90 billion, a P/E ratio of -219.31, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The business’s 50-day moving average price is $486.76 and its 200 day moving average price is $465.31. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88.

Dogwood Therapeutics (DWTX)

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.

Dogwood Therapeutics stock traded up $2.19 during midday trading on Monday, hitting $6.46. 17,487,441 shares of the company’s stock were exchanged, compared to its average volume of 3,536,523. The stock has a market cap of $12.35 million, a PE ratio of -0.99 and a beta of 1.99. Dogwood Therapeutics has a 12-month low of $1.62 and a 12-month high of $29.28. The business has a 50 day moving average price of $5.37.